Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate
Newly Public Gene Therapy Biotech Avrobio Picks Up Two Sell-Side Bulls
Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation
Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate
David Lebowitz Recent News
Insmed Has $700M Opportunity With Lung Disease Treatment, Says Morgan Stanley
Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy
As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?
Sarepta's Upside Story Is Just Getting Started
Data Monitoring Committee Determines Alnylam's ENDEAVOUR Trial May Continue
Raptor Pharmaceuticals Buys Quinsair: What You Need To Know